Therapeutic Effect of Imatinib Made in Real World to Newly Diagnosed Chronic Myeloid Leukemia / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 456-461, 2021.
Article
em Zh
| WPRIM
| ID: wpr-880097
Biblioteca responsável:
WPRO
ABSTRACT
OBJECTIVE@#To evaluate the clinical efficacy and safety of domestic imatinib (made in China) in patients with newly diagnosed chronic myeloid leukemia chronic phase(CML-CP).@*METHODS@#Fifty-seven newly diagnosed CML-CP patients who did not receive any other anti-CML treatment were treated by domestic imatinib 400 mg once a day. The hematological, cytogenetic and molecular reactions and safety were observed and evaluated after 3, 6 and 12 months of treatment.@*RESULTS@#Fifty-six patients were treated for ≥3 and 6 months, among which 50 patients were treated for ≥12 months. After 3 months of treatment, 49 patients underwent hematological examination, 47 patients (95.9%) achieved complete hematological response (CHR), 49 patients underwent cytogenetic examination, 39 patients (79.6%) achieved major cytogenetic response (MCyR), and 12 patients (24.5%) achieved complete cytogenetic response (CCyR). 49 patients underwent the level of BCR-ABL test, including 41 patients (83.7%) with BCR-ABL@*CONCLUSION@#In the real world, Domestics imatinib mesylate is effective and safe in the treatment of newly diagnosed CML-CP patients, but long-term follow-up data are still necessary to verify its long-term efficacy.
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Piperazinas
/
Pirimidinas
/
Benzamidas
/
Leucemia Mielogênica Crônica BCR-ABL Positiva
/
China
/
Proteínas de Fusão bcr-abl
/
Resultado do Tratamento
/
Mesilato de Imatinib
/
Antineoplásicos
Limite:
Humans
País como assunto:
Asia
Idioma:
Zh
Ano de publicação:
2021
Tipo de documento:
Article